I think they could actually do quite a bit better than that if they get a good label and they have the ability to market the quick onset of action.
This is actually the first drug in this class that seems to have a clean enough profile so that I could maybe see some country (not the US) eventually allowing OTC use.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.